Brief: Bavarian Nordic Gets Acceptance From Health Canada For Review Of New Drug Submission For Chikungunya Vaccine
July 22 (Reuters) - Bavarian Nordic A/S BAVA.CO: BAVARIAN NORDIC RECEIVES ACCEPTANCE FROM HEALTH CANADA FOR REVIEW OF THE NEW DRUG SUBMISSION FOR ITS CHIKUNGUNYA VACCINE REVIEW PROCEDURE BEGINS FOR CHIKUNGUNYA VACCINE, APPROVAL POSSIBLE IN 2026 Source text: ID:nGNXbBPBQ3 Further company coverage: BAVA.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on Bavarian Nordic A/S
See all newsBrief: Bavarian Nordic Completes First Tranche Of Share Buy-Back Program
Bavarian Nordic gets four-year contract for mpox and smallpox vaccine from UK government
Brief: Bavarian Nordic Awarded Multi-Year Vaccine Contract By UK Government
Bavarian Nordic donates 75,000 mpox vaccine doses to global emergency stockpile
Brief: Bavarian Nordic Donates To Global Mpox Emergency Stockpile